Beyond Air (NASDAQ:XAIR) & AtriCure (NASDAQ:ATRC) Head-To-Head Survey
their valuation, analyst recommendations, profitability, risk, dividends, institutional ownership and earnings. Both companies are medical focused, but Beyond Air is the better business according to their valuation, analyst recommendations, profitability, risk, dividends, institutional ownership
Which is the superior business? We will compare these two companies based on their earnings, dividends, analyst recommendations, and institutional ownership.
Insiders and Institutional Ownership
Institutional investors hold 19.0% of Beyond Air's shares. 95.3% AtriCure's shares are owned by institutional investors. Insiders own 15.6% of Beyond Air's shares. Comparatively 3.0% of AtriCure's shares are owned by insiders. MarketBeat.com has provided a list of ratings and recommendations for Beyond Air, and AtriCure.
Sell Ratings
Hold Ratings
Buy Ratings
Strong Buy Ratings
Rating Score
Beyond Air
0
0
2
0
3.00
AtriCure
0
0
5
0
3.00
Beyond Air has a current consensus target price at $21.50. This indicates a potential upward movement of 302.62%. AtriCure's consensus target price is $59.83. This indicates a potential upward movement of 27.49%. Research analysts clearly believe Beyond Air to be more favorable due to its higher potential upside.
Profitability
The table below compares the net margins of Beyond Air and AtriCure, as well as their return on equity and assets.
Net Margins
Return on Equity
Return on Assets
Beyond Air
N/A
-63.60%
-49.23%
AtriCure
-10.81%
-9.18%
-7.14%
Volatility and Risk
Beyond Air's beta is -0.31, which means that its stock price has 131% lower volatility than the S&P 500. AtriCure, on the other hand, has a beta value of 1.35. This means that its stock is 35% volatile than S&P 500.
Value & Earnings
This table compares Beyond Air's gross revenues, earnings per share and valuation with AtriCure.
Gross Revenue
Price/Sales Ratio
Net Income
Earnings per Share
Price/Earnings ratio
Beyond Air
$870,000.00
184.70
-$43.18 millions
($1.93)
-2.77
AtriCure
$330.38 Million
6.70
-$46.47 Million
($0.82)
-57.23
Beyond Air's earnings are higher, but its revenue is lower than AtriCure. AtriCure has a lower Price-to-Earnings Ratio than Beyond Air. This indicates that AtriCure's stock is more affordable.
You can read more about it here:
AtriCure beats Beyond Air in 7 out of 13 factors when comparing the two stocks.
What Beyond Air?
Get Rating
)
Beyond Air, Inc., a medical device and biopharmaceutical firm in clinical stages, is located in the United States. It develops a nitric-oxide generator and delivery system which uses ambient air to produce nitric-oxide and deliver precise amounts of it into the lungs in order to treat respiratory diseases and other illnesses. The company operates in the Beyond Air segment and Beyond Cancer segment. The company developed the LungFit system, which is a generator system and delivery system for nitric dioxide that can be produced from ambient air without the use of expensive and bulky cylinders. The company was established in 2011 in Garden City, NY.
AtriCure
Get Rating
)
AtriCure, Inc. is a company that develops, manufactures, and sells systems for surgical ablation of heart tissue and the exclusion left atrial appendage. The company's products include radiofrequency (RF) ablation, pacing and sensoring, cryo and left atrial appendage, soft tissue management, Estech surgical instruments, cart configuration, and more. It is divided into four geographical segments: United States (including Canada), Europe (including the UK), Asia and Other International. MarketBeat.com offers a FREE daily email newsletter
.